London, United Kingdom 2013 Poster Session Red Cerebrovasc Dis 2013; 35 (suppl 3)1-854 329 92 Stroke prognosis Relationship of body mass index and long term mortality for acute ischemic stroke patients treated with thrombolysis E.G. Kim1, J.W. Seo2 Inje University,Paik Hospital, Pusan, SOUTH KOREA1, Inje University,Paik Hospital, Pusan, SOUTH KOREA2 Background Obesity is an established risk factor for ischemic stroke and coronary disease. Recently, a few data suggest that obese and overweight stroke patients have significant better long-term survival rates(obesity paradox). This study was to investigate the independent association between body mass index(BMI) and mortality for acute ischemic stroke patients treated with intravenous-recombi-nant tissue plasminogen activator(IV rtPA) and/or intra-arterial thrombolysis(IAT). Methods During 8 years, 315 of 352 patients treated with IV rtPA or IAT were included. The study patients were divided into 4 groups according to BMI: underweight(<18.5kg/m2), normal weight(18.5-23kg/ m2), overweight(23-25kg/m2), and obese(>25kg/m2). Neurologic severity was estimated by NIHSS and mRS. Information for long-term mortality and mRS was collected until July, 2012. We com-pared baseline characteristics including demographics, systolic blood pressure, LDL, total cholester-ol, glucose level at admission, stroke subtypes, thrombolytic methods, and risk factors like diabetics, hypertension, atrial fibrillation and dyslipidemia. Results In underweight stroke patients, age, NIHSS and mRS on admission were significantly higher com-pared to that of other BMI groups. Similarly, mRS at discharge of underweight stroke group was significantly higher than mRS at discharge of other BMI groups. Overweight and obese patients had a significantly higher incidence of hypertension than underweight patients. Long-term mortality rate in underweight patients seemed to be higher compared to that of other BMI groups, however it was not significant. Conclusions Based on BMI, underweight stroke patients do not have significantly worse long-term survival rates compared to patients with other BMI. 93 Stroke prognosis EFFECTS OF PRIOR TREATMENT WITH ANTIPLATELETS ON ISCHEMIC STROKE SEVERITY AND OUTCOME K. Tziomalos1, S.D. Bouziana2, M. Spanou3, A. Pavlidis4, V. Giampatzis5, M Papadopoulou6, G. Kagelidis7, A. Kouparanis8, C. Savopoulos9, A.I. Hatzitolios10 Stroke Unit, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE1, Stroke Unit, First Pro-pedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE2, Stroke Unit, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE3, Stroke Unit, First Propedeutic Department of Internal Medicine, Medical School, Aris-totle University of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE4, Stroke Unit, First Pro-pedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE5, Stroke Unit, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE6, Stroke Unit, First Propedeutic Department of Internal Medicine, Medical School, Aris-totle University of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE7, Stroke Unit, First Pro-pedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE8, Stroke Unit, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE9, Stroke Unit, First Propedeutic Department of Internal Medicine, Medical School, Aristotle Universi-ty of Thessaloniki, AHEPA Hospital, Thessaloniki, GREECE10 Background: In patients with acute myocardial infarction, prior treatment with antiplatelets is as-sociated with better outcome. It is unclear whether this beneficial effect of antiplatelets is observed in patients with acute ischemic stroke (IS). Methods: We prospectively studied 378 patients who were hospitalized for IS (38.9% males, age 78.8+/-6.5 years). The severity of IS was assessed with the National Institute of Health stroke scale (NIHSS) score at admission and the outcome was as-sessed with the modified Rankin scale (mRS) score at discharge. Results: At admission, 160 patients (42.3%) were on antiplatelets (aspirin, clopidogrel, triflusal). These patients had a higher prevalence of type 2 diabetes (38.1 vs. 28.0% in patients not on antiplatelets; p<0.05), coronary heart disease (45.9 vs. 15.6%, respectively; p<0.001), history of IS (58.8 vs. 27.8%, respectively; p<0.001), heart failure (32.5 vs. 16.2%, respectively; p=0.001) and obesity (29.8 vs. 16.5%, respectively; p<0.05). On the other hand, patients on antiplatelets had at admission lower systolic blood pressure (BP) (142+/-22 vs. 149+/-25 mmHg in patients not on antiplatelets; p<0.01), lower diastolic BP (79+/- 11 vs. 82+/-14 mmHg, respectively; p<0.05) and lower LDL-C levels (105+/-43 vs. 120+/-35 mg/ dl, respectively; p<0.05). Other cardiovascular risk factors did not differ between the two groups. At admission, the NIHSS score was similar in patients on antiplatelets and in those not on antiplatelets (9.3+/-8.6 vs. 8.6+/-9.7, respectively; p=NS). At discharge, the mRS score did not differ between the two groups (2.6+/-2.2 vs. 2.7+/-2.2, respectively; p=NS). Conclusion: Prior treatment with antiplate-lets in patients with IS does not appear to be associated with less severe IS or with better outcome. However, it cannot be excluded that patients with a history of cardiovascular disease (CVD) could have suffered a more severe stroke, which has been moderated by antiplatelets to the severity of stroke in patients without CVD.
Karger_ESC London_2013
To see the actual publication please follow the link above